Hansoh Pharma's Investigational Therapy for Small Cell Lung Cancer Granted Priority Review by Chinese Regulator
Stock News
Sep 11
Hansoh Pharma (03692) has announced that its investigational drug, Injectable Ruikang Livotamab (HS-20093), has been accepted into the priority review and approval process by China's National Medical Products Administration (NMPA).
This designation, confirmed on August 21, 2026, follows the positive results from the pivotal Phase III trial, ARTEMIS-008. The therapy is intended for patients with small cell lung cancer who have previously been treated with platinum-based chemotherapy and have experienced disease progression.
The inclusion in the priority review program is expected to expedite the regulatory evaluation and potential market approval of this treatment for this specific patient population.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.